Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Debt to Equity (2020 - 2023)

Historic Debt to Equity for Silo Pharma (SILO) over the last 4 years, with Q1 2023 value amounting to $0.07.

  • Silo Pharma's Debt to Equity rose 81690.5% to $0.07 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.07, marking a year-over-year increase of 81690.5%. This contributed to the annual value of $0.04 for FY2022, which is 2362.84% down from last year.
  • Latest data reveals that Silo Pharma reported Debt to Equity of $0.07 as of Q1 2023, which was up 81690.5% from $0.04 recorded in Q4 2022.
  • Over the past 5 years, Silo Pharma's Debt to Equity peaked at $0.07 during Q1 2023, and registered a low of $0.0 during Q1 2021.
  • Over the past 4 years, Silo Pharma's median Debt to Equity value was $0.01 (recorded in 2021), while the average stood at $0.02.
  • As far as peak fluctuations go, Silo Pharma's Debt to Equity surged by 129104.04% in 2021, and later tumbled by 8046.58% in 2022.
  • Quarter analysis of 4 years shows Silo Pharma's Debt to Equity stood at $0.0 in 2020, then soared by 1291.04% to $0.05 in 2021, then decreased by 23.63% to $0.04 in 2022, then soared by 98.51% to $0.07 in 2023.
  • Its Debt to Equity stands at $0.07 for Q1 2023, versus $0.04 for Q4 2022 and $0.0 for Q3 2022.